Acurx Pharmaceuticals (ACXP) closed at $0.99 on November 12, 2026, down 4.4% from the previous close, on volume of 138,984 shares (30-day average 84,618).
Data as of November 12, 2026.
Acurx Pharmaceuticals GAAP EPS of -$0.49
Seeking Alpha News (Thu, 12-Nov 7:25 AM ET)
Acurx Pharmaceuticals, Inc. Reports Third Quarter 2026 results and provides business update
PRNewswire (Thu, 12-Nov 7:01 AM ET)
PRNewswire (Mon, 26-Oct 8:02 AM ET)
PRNewswire (Wed, 21-Oct 8:02 AM ET)
PRNewswire (Tue, 29-Sep 8:01 AM ET)
PRNewswire (Mon, 17-Aug 8:01 AM ET)
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2026 results and provides business update
PRNewswire (Fri, 14-Aug 7:01 AM ET)
Market Chameleon (Tue, 10-Mar 6:29 AM ET)
Acurx Unveils Promising Microbiome-Sparing Antibiotics: Class Effect May Revolutionize CDI Treatment
Market Chameleon (Tue, 28-Oct 5:09 AM ET)
Market Chameleon (Thu, 9-Oct 4:19 AM ET)
Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.
Acurx Pharmaceuticals trades on the NASDAQ stock market under the symbol ACXP.
As of November 13, 2026, ACXP stock price climbed to $0.99 with 80,544 million shares trading.
ACXP has a beta of -1.42, meaning it tends to be less sensitive to market movements. ACXP has a correlation of 0.02 to the broad based SPY ETF.
ACXP has a market cap of $5.42 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, ACXP traded as high as $105.60 and as low as $.95.
The top ETF exchange traded funds that ACXP belongs to (by Net Assets): VXF.
ACXP has underperformed the market in the last year with a price return of -80.1% while the SPY ETF gained +10.8%. ACXP has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -35.7% and -7.5%, respectively, while the SPY returned -2.7% and -2.5%, respectively.
ACXP support price is $.93 and resistance is $1.05 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACXP shares will trade within this expected range on the day.
